Orthofix Medical Inc. (OFIX) has reported a significant uptick in revenue for the first quarter of 2025, marking an 18% to 19% increase compared to the same period in 2024. This growth is primarily attributed to strong performances in their orthobiologics segment and increased income from licensing.
The rise in revenue highlights the effectiveness of Orthofix's strategic focus on expanding these high-growth areas. Orthobiologics, known for its innovative biologics solutions, has been a key driver, alongside lucrative licensing agreements that have further bolstered the company's financial position.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Xtant Medical Holdings Inc (XTNT, Financial) is $1.75 with a high estimate of $2.00 and a low estimate of $1.50. The average target implies an upside of 348.72% from the current price of $0.39. More detailed estimate data can be found on the Xtant Medical Holdings Inc (XTNT) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Xtant Medical Holdings Inc's (XTNT, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Xtant Medical Holdings Inc (XTNT, Financial) in one year is $0.96, suggesting a upside of 146.15% from the current price of $0.39. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Xtant Medical Holdings Inc (XTNT) Summary page.
